Safety and Pharmacokinetics of Exebacase in an Infant with Disseminated Staphylococcus aureus Infection.

Journal Article (Journal Article)

Exebacase, an anti-staphylococcal lysin produced from a bacteriophage-encoded gene, is a promising adjunctive therapy for severe methicillin-resistant Staphylococcus aureus infections. We describe the first infant to receive exebacase, dosing, and pharmacokinetics (PK). Exebacase may be safe and efficacious in children; however, further clinical trials are needed to optimize dosing.

Full Text

Duke Authors

Cited Authors

  • Moorthy, GS; Greenberg, RG; Hornik, CD; Cassino, C; Ghahramani, P; Kumar, KR; Fowler, VG; Cohen-Wolkowiez, M

Published Date

  • December 11, 2021

Published In

PubMed ID

  • 34894129

Electronic International Standard Serial Number (EISSN)

  • 1537-6591

Digital Object Identifier (DOI)

  • 10.1093/cid/ciab1015


  • eng

Conference Location

  • United States